HOME CAREERS CONTACT
 
Investor Relations


Stock Information
NASD:OLGC
$0.94  
May 9, 2008
4:00 PM ET
Quotes delayed at least 20 minutes.
Information provided by TurboFeed.
OrthoLogic is a biotechnology company committed to developing a pipeline of novel therapeutic peptides and other molecules aimed at helping patients with under-served medical conditions. The Company is focused on the development and commercialization of two product platforms: Chrysalin® (TP508) and AZX100.

Chrysalin, the Company’s novel synthetic 23-amino acid peptide, is being studied in several indications including fracture repair, diabetic foot ulcer healing and other disorders that may involve vascular endothelial dysfunction. The Company owns exclusive worldwide rights to Chrysalin.

AZX100 is a novel synthetic pre-clinical 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary disease, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. OrthoLogic has an exclusive worldwide license to AZX100.

OrthoLogic’s corporate headquarters are in Tempe, Arizona.

 

OrthoLogic Annual Shareholder Meeting

May 9, 2008 at 8:00 AM PT
Phoenix Hilton Airport
2435 South 47th Street
Phoenix, AZ 85O34
2007 Annual Report
 
OrthoLogic Scheduled Conference Calls
May 12, 2008 at 4:30 PM ET
Webcast Orthologic First Quarter 2008 Financial Results
Mar 5, 2008 at 4:30 PM ET
Webcast OrthoLogic Year-End 2007 Financial Results
Nov 6, 2007 at 8:30 AM ET
Webcast OrthoLogic Third Quarter 2007 Financial Results
View all events & presentations »

Contact Information
Primary IR Contact Transfer Agent
Investor Relations Contact: Karen Struck
Phone: 602–286-5250
E-mail: investorinquiries@olgc.com

The Bank of New York
Phone: 1-800-524-4458

       
Copyright © 2007 OrthoLogic. All Rights Reserved. | Legal Disclaimer